Detecting Central and Peripheral Biomarkers in MDD
Information source: Centre for Addiction and Mental Health
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Major Depressive Disorder
Intervention: phenelzine treatment (Other)
Phase: N/A
Status: Recruiting
Sponsored by: Centre for Addiction and Mental Health Official(s) and/or principal investigator(s): Jeffrey H. Meyer, MD, PhD, Principal Investigator, Affiliation: Research Imaging Centre, Centre for Addiction and Mental Health
Overall contact: Laura Miler, Phone: 416.535.8501, Ext: 34386
Summary
The purpose of this study is to determine if monoamine oxidase B (MAO-B) total distribution
volume (VT), after phenelzine treatment and if so to what extent.
Clinical Details
Official title: Detecting Central and Peripheral Biomarkers in Major Depressive Disorder (MDD)
Study design: Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: MAO-B VT levels measured with PET in MDE secondary to MDD
Detailed description:
Subjects will receive a PET and MRI scan before and after treatment with phenelzine.
Eligibility
Minimum age: 18 Years.
Maximum age: 80 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- 18-80 years of age
- good physical health
- Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) diagnosis of current
major depressive episode (MDE)
- DSM-IV diagnosis of major depressive disorder (MDD) verified by SCID for DSM-IV and a
psychiatric consultation
- greater than 17 on the 17 item HDRS (Hamilton Depression Rating Scale).
- history of non-response to several different antidepressant classes
Exclusion Criteria:
- herbal, drug or medication use (that affect CNS function)
- suicide attempts
- drug or medication use within eight weeks (+5 half lives of medication)
- history of substance abuse or any neurotoxin use
- history of psychotic symptoms
- history of central nervous system (CNS) medical illness
- current substance abuse
- test positive on pregnancy test (for women)
Locations and Contacts
Laura Miler, Phone: 416.535.8501, Ext: 34386
Center for Addiction and Mental Health, Toronto, Ontario M5T 1R8, Canada; Recruiting Laura Miler, Phone: 416-535-8501, Ext: 34386 Jeffrey Meyer, MD PhD, Principal Investigator
Additional Information
Information about research at the Centre for Addiction and Mental Health
Starting date: June 2014
Last updated: June 23, 2015
|